ADMA Biologics Operating Income Over Time
| ADMA Stock | USD 15.93 0.02 0.13% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ADMA Biologics Performance and ADMA Biologics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.12 | Return On Assets | Return On Equity |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare ADMA Biologics and related stocks such as ACADIA Pharmaceuticals, Praxis Precision Med, and Belite Bio ADR Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACAD | (11.3 M) | (22.9 M) | (20.9 M) | (38.3 M) | (93.2 M) | (164.6 M) | (272.8 M) | (292.4 M) | (247.4 M) | (246.5 M) | (286.6 M) | (170.4 M) | (223.6 M) | (73.4 M) | 230.8 M | 207.7 M | 218.1 M |
| PRAX | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (22.7 M) | (35.8 M) | (62 M) | (167.3 M) | (215 M) | (126.4 M) | (200.2 M) | (180.1 M) | (189.2 M) |
| BLTE | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (9.8 M) | (12.8 M) | (31.7 M) | (40 M) | (36 M) | (34.2 M) |
| LGND | (20.9 M) | (698 K) | 574 K | 14.9 M | 19.6 M | 27.3 M | 43.9 M | 68.1 M | 163.7 M | 807.1 M | 37.5 M | 103.9 M | 3 M | 11.9 M | (22.6 M) | (26 M) | (24.7 M) |
| SLNO | (3.6 M) | (3.6 M) | (3.6 M) | (846.8 K) | (5.2 M) | (12.2 M) | (13.6 M) | (12.2 M) | (14.3 M) | (23.2 M) | (31.9 M) | (31.5 M) | (24.4 M) | (41.4 M) | (187.7 M) | (168.9 M) | (160.5 M) |
| MIRM | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (54.7 M) | (104.3 M) | (173.4 M) | (131.2 M) | (109.2 M) | (87.6 M) | (78.8 M) | (82.8 M) |
| DYN | 605 M | (236 M) | 714 M | (318 M) | (318 M) | 64 M | (640 M) | (412 M) | (4.8 M) | (13.8 M) | (58.6 M) | (150 M) | (171 M) | (242.2 M) | (343.9 M) | (309.5 M) | (294 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.1 M) | (28.7 M) | (53.8 M) | (75 M) | (107.7 M) | (167.9 M) | (222.6 M) | (338.9 M) | (305 M) | (289.7 M) |
| TLX | (578 K) | (35.4 K) | (1.9 M) | (1.9 M) | (5.1 M) | (116 K) | (30 K) | (6.4 M) | (15.7 M) | (40.3 M) | (49.3 M) | (81.2 M) | (91.9 M) | 51.9 M | 82.1 M | 73.9 M | 77.6 M |
| RARE | (6.6 M) | (6.6 M) | (16 M) | (32.3 M) | (56.8 M) | (147.7 M) | (248 M) | (328.9 M) | (371.4 M) | (424.2 M) | (330.1 M) | (381.7 M) | (648.9 M) | (569.2 M) | (536 M) | (535 M) | (508.2 M) |
ADMA Biologics and related stocks such as ACADIA Pharmaceuticals, Praxis Precision Med, and Belite Bio ADR Operating Income description
Operating Income is the amount of profit realized from ADMA Biologics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of ADMA Biologics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| ADMA Biologics | ADMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 465 State Route |
| Exchange | NASDAQ Exchange |
USD 15.93
Check out ADMA Biologics Performance and ADMA Biologics Correlation. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
ADMA Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.